NICE Single Technology Appraisal Guidance No 253
Boceprevir for the treatment of genotype 1 chronic hepatitis
C
This NICE guidance was published on 25 April
2012. The web reference for the appraisal and other related
documents is: www.nice.org.uk/TA253
NHSScotland should note
that:
- Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
- NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published Statements of Advice (722/11 and
723/11) on this medication for this indication in October 2011.
Separate submissions were considered in relation to patients whose
previous treatment has failed and patients not previously treated.
The advice stated that:
boceprevir (Victrelis®) is accepted for use
within NHSScotland for the treatment of chronic hepatitis C (HCV)
genotype 1 infection, in combination with peginterferon alfa and
ribavirin, in adult patients with compensated liver disease who
have failed previous therapy.
And:
boceprevir (Victrelis®) is accepted for use
within NHSScotland for the treatment of chronic hepatitis C (HCV)
genotype 1 infection, in combination with peginterferon and
ribavirin, in adult patients with compensated liver disease who are
previously untreated.
Access the advice of SMC:
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in the first
instance tel 0141 225 6873
Published Date: 25 April 2012
